Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-hfldf Total loading time: 0 Render date: 2024-05-31T13:57:18.570Z Has data issue: false hasContentIssue false

25 - Analgesic Effects of Botulinum Toxins

from Section II - Botulinum Toxin Therapy

Published online by Cambridge University Press:  31 May 2018

By
Zdravko Lacković  and
Maja Relja
Edited by
Dirk Dressler ,
Eckart Altenmüller  and
Joachim K. Krauss
Dirk Dressler
Affiliation:
Hannover Medical School
Eckart Altenmüller
Affiliation:
Hochschule für Musik, Theater und Medien, Hannover
Joachim K. Krauss
Affiliation:
Hannover Medical School
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Treatment of Dystonia , pp. 115 - 119
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agafonova, NV, Khasanova, DR (2014) [The use of different doses of botulotoxin A in the treatment of early arm poststroke spasticity]. [Article in Russian] Zh Nevrol Psikhiatr Im S S Korsakova 114: 68–71.Google ScholarPubMed
Aoki, R (2002) Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40: 923–928.Google Scholar
Arnouk, R, Suzuki Bellucci, C, Benatuil Stull, R, de Bessa, J, Malave, C, Gomes, C (2012) Botulinum neurotoxin type A for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. Sci World J 2012: 463574.Google Scholar
Bach-Rojecky, L, Lacković, Z (2005) Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J 46: 201–208.Google Scholar
Bach-Rojecky, L, Lacković, Z (2009) Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav 94(2): 234–238. doi: 10.1016/j.pbb.2009.08.012.Google Scholar
Basciani, M, DiRienzo, F, Fontana, A, Copetti, M, Pellegrini, F, Intiso, D (2011) Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses. Dev Med Child Neurol 53: 559–564.Google Scholar
Bittencourt da Silva, L, Karshenas, A, Bach, F, Rasmussen, S, Arendt-Nielsen, L, Gazerani, P (2014) Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study. Pain Res Manag 19: 126–132.Google Scholar
Camargo, C, Cattai, L, Teive, H (2015) Pain relief in cervical dystonia with botulinum toxin treatment. Toxins (Basel) 7: 2321–2335.CrossRefGoogle ScholarPubMed
Cui, M, Khanijou, S, Rubino, J, Aoki, K (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107: 125–133.CrossRefGoogle ScholarPubMed
Currà, A, Berardelli, A (2009) Do the unintended actions of botulinum toxin at distant sites have clinical implications? Neurology 72:1095–1099.Google Scholar
Dodick, D, Turkel, C, DeGryse, R, Aurora, S, Silberstein, S, Lipton, R, Diener, H, Brin, MF, PREEMPT Chronic Migraine Study Group (2010) OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind randomized placebo-controlled phases of the PREEMPT clinical program. Headache 50: 921–936.CrossRefGoogle ScholarPubMed
Dressler, D, Adib Saberi, F (2013) Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox doses. J Neural Transm 120: 1565–1567.Google Scholar
Dressler, D, Benecke, R (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49: 34–38.CrossRefGoogle ScholarPubMed
Dressler, D, Eleopra, R (2006) Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res 9: 121–125.Google Scholar
Fedorowicz, Z, van Zuuren, E, Schoones, J (2013) Botulinum toxin for masseter hypertrophy. Cochrane Database of Systematic Reviews 9(9): CD007510.Google Scholar
Göbel, H, Heinze, A, Reiche, G, Hefter, H, Benecke, R, Dysport Myofascial Pain Study Group (2006) Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study. Pain 125: 82–88.Google Scholar
Hu, Y, Guan, X, Fan, L, Li, M, Liao, Y, Nie, Z, Jin, L (2013) Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review. J Headache Pain 14: 72.CrossRefGoogle ScholarPubMed
Intiso, D, Basciani, M, Santamato, A, Intiso, M, Di Rienzo, F (2015) Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins 7: 2454–2480.CrossRefGoogle ScholarPubMed
Kollewe, K, Mohammadi, B, Köhler, S, Pickenbrock, H, Dengler, R, Dressler, D (2015) Blepharospasm: long-term treatment with either Botox® Xeomin® or Dysport®. J Neural Transm 122: 427–431.Google Scholar
Langevin, P, Peloso, PM, Lowcock, J, Nolan, M, Weber, J, Gross, A, Roberts, J, Goldsmith, CH, Graham, N, Burnie, SJ, Haines, T (2011) Botulinum toxin for subacute/chronic neck pain. Cochrane Database Syst Rev 7: CD008626.Google Scholar
Marino, MJ, Terashima, T, Steinauer, JJ, Eddinger, KA, Yaksh, TL, Xu, Q (2014) Botulinum toxin B in the sensory afferent: transmitter release spinal activation and pain behavior. Pain 155: 674–684.CrossRefGoogle ScholarPubMed
Matak, I, Lacković, Z (2014) Botulinum toxin A brain and pain. Prog Neurobiol 119–120: 39–59.CrossRefGoogle ScholarPubMed
Matak, I, Lacković, Z (2015) Botulinum neurotoxin type A: actions beyond SNAP-25. Toxicology 335: 79–84.CrossRefGoogle ScholarPubMed
Mense, S (2004) Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 251(Suppl. 1): 1–7.CrossRefGoogle ScholarPubMed
Relja, M, Klepac, N (2002) Different doses of botulinum toxin A and pain responsiveness in cervical dystonia. Neurology 58: A474.Google Scholar
Relja, M, Poole, AC, Schoenen, J, Pascual, J, Lei, X, Thompson, C, European BoNTA Headache Study Group (2007) A multicentre double-blind randomized placebo-controlled parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27: 492–503.Google Scholar
Singh, JA, Fitzgerald, PM (2011) Botulinum toxin for shoulder pain: a Cochrane systematic review. J Rheumatol 38(3): 409–418.Google Scholar
Soares, A, Andriolo, RB, Atallah, AN, da Silva, EM (2012) Botulinum toxin for myofascial pain syndromes in adults. Cochrane Database Syst Rev 4: CD007533.Google Scholar
Tsui, JK, Eisen, A, Stoessl, AJ, Calne, S, Calne, DB (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2: 245–247.Google Scholar
Waseem, Z, Boulias, C, Gordon, A, Ismail, F, Sheean, G, Furlan, AD (2010) Botulinum toxin injections for low-back pain and sciatica. Cochrane Database Syst Rev 1: CD008257.Google Scholar
Winocour, S, Murad, MH, Bidgoli-Moghaddam, M, Jacobson, SR, Bite, U, Saint-Cyr, M, Tran, NV, Lemaine, V (2014) Systematic review of the use of botulinum toxin type A with subpectoral breast implants. J Plast Reconstr Aesthet Surg 67: 34–41.Google Scholar
Wu, T, Fu, Y, Song, HX, Ye, Y, Dong, Y, Li, JH (2015) Effectiveness of botulinum toxin for shoulder pain treatment: a systematic review and meta-analysis. Arch Phys Med Rehabil 16(15).Google Scholar
Zhang, H, Lian, Y, Ma, Y, Chen, Y, He, C, Xie, N, Wu, C (2014) Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized double-blind placebo-controlled trial. J Headache Pain 15: 65.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×